Lexaria Bioscience financials
$3.13−2.95%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q3 '26 May 31 | Q2 '26 Feb 28 | Q1 '26 Nov 30 | Q4 '25 Aug 31 | Q3 '25 May 31 | Q2 '25 Feb 28 | Q1 '25 Nov 30 | Q4 '24 Aug 31 | Q3 '24 May 31 | Q2 '24 Feb 29 | Q1 '24 Nov 30 | Q4 '23 Aug 31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $20.0K | $0.00 | $174.0K | $174.0K | $174.0K | $183.9K | $84.0K | $84.0K | $145.0K | $151.3K | $30.7K |
| Gross profit | $0.00 | $20.0K | $0.00 | $174.0K | $174.0K | $174.0K | $181.2K | $84.0K | $84.0K | $145.0K | $146.5K | $30.7K |
| Gross margin | — | 100.0% | — | 100.0% | 100.0% | 100.0% | 98.5% | 100.0% | 100.0% | 100.0% | 96.8% | 100.0% |
| Operating income | -$2.0M | -$1.5M | -$1.6M | -$2.7M | -$3.8M | -$2.8M | -$2.7M | -$2.2M | -$1.7M | -$668.0K | -$1.1M | -$1.1M |
| Net income | -$2.0M | -$1.4M | -$1.6M | -$2.7M | -$3.8M | -$2.7M | -$2.7M | -$2.2M | -$1.8M | -$649.5K | -$1.2M | -$1.2M |
| Net margin | — | −7249.9% | — | −1549.3% | −2177.6% | −1559.3% | −1470.0% | −2600.9% | −2121.1% | −448.0% | −779.6% | −4031.5% |
| Diluted EPS | $-1.20 | $-0.90 | $-1.05 | $-2.07 | $-3.15 | $-2.25 | $-2.40 | $-2.07 | $-1.95 | $-0.90 | $-1.95 | $-2.29 |
| EBITDA | -$2.0M | -$1.4M | -$1.6M | -$2.7M | -$3.7M | -$2.7M | -$2.7M | -$2.2M | -$1.7M | -$652.1K | -$1.1M | -$1.0M |
| Operating cash flow | -$1.6M | -$2.2M | -$984.1K | -$2.6M | -$3.6M | -$1.5M | -$2.7M | -$1.9M | -$1.3M | -$619.6K | -$1.2M | -$1.6M |
| Free cash flow | -$1.6M | -$2.2M | -$984.1K | -$2.6M | -$3.6M | -$1.5M | -$2.8M | -$1.9M | -$1.3M | -$659.6K | -$1.2M | -$1.6M |
| Diluted shares | 1.7M | 1.6M | 1.4M | 1.3M | 1.2M | 1.2M | 1.1M | 1.1M | 0.9M | 0.7M | 0.6M | 0.5M |
Balance sheet
| Period end | May 31 | Feb 28 | Nov 30 | Aug 31 | May 31 | Feb 28 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $3.5M | $5.1M | $4.3M | $1.8M | $4.6M | $6.5M |
| Short-term investments | $142.1K | $141.3K | $143.3K | $165.4K | $33.5K | $73.9K |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $4.8M | $6.5M | $6.1M | $4.2M | $6.7M | $8.7M |
| Total liabilities | $437.1K | $277.0K | $1.5M | $1.6M | $1.6M | $1.9M |
| Shareholders' equity | $4.3M | $6.2M | $4.5M | $2.6M | $5.2M | $6.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology